IBRX ImmunityBio, Inc.
$8.81▲ +2.09%
Healthcare
Other
After hours
$8.75▼ -0.68%
Oct 28, 7:59 PM ET
Volume 7.14M
Avg Volume (10D) 15.72M
Key Metrics & Fundamentals
Market Cap
$9.34B
P/E Ratio
–
Div Yield
0.00%
52W Range
1.95 - 12.43
% vs 50 MA
1.43%
% vs 200 MA
12.28%
RSI-14
49.1
MACD Histogram
-0.1600
Beta (1Y vs SPY)
1.60
Free Cash Flow
-$70.03M
Gross Rev
$51.24M
Gross Profit
$50.94M
EBITDA
-$149.86M
COGS
$298,000
Operating Exp
$112.64M
Operating Income
-$61.70M
EBIT
-$61.70M
Pretax Income
-$230.39M
Net Income
-$230.38M
EPS (Diluted)
-0.22
Price & Volume History
Loading chart…
Recent News
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
Stocktwits · Oct 27, 2026 3:14 AM ET
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
Zacks · Oct 22, 2026 8:40 AM ET
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
Stocktwits · Oct 21, 2026 9:35 AM ET
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
Business Wire · Oct 21, 2026 7:30 AM ET
ANKTIVA Label Expansion Could Change The Case For ImmunityBio Stock
Simply Wall St. · Oct 19, 2026 6:20 PM ET
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Business Wire · Oct 16, 2026 11:49 AM ET
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
Zacks · Oct 15, 2026 11:56 AM ET
IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk
Stocktwits · Oct 14, 2026 9:29 PM ET
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Business Wire · Oct 14, 2026 4:18 PM ET
IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline
Stocktwits · Oct 14, 2026 1:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See IBRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.